Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes
Hims & Hers (HIMS) stock is down ~40% YTD but remains a "Buy." Learn why compressed valuation and Eucalyptus-led Europe/Japan ...
Blockonomi
Hims & Hers (HIMS) Stock Plummets 39% Amid GLP-1 Strategy Shift and Margin Pressure
Hims & Hers (HIMS) stock fell 39% in 2026 after shifting to branded GLP-1 drugs. Amazon's Foundayo launch adds pressure.
NUTRITION and FITNESS
Celebrity chef and restaurant owner Andrew Gruel joins ‘Varney & Co.’ to break down the surprising ways weight loss drugs are hitting restaurant menus, alcohol sales and profit margins across the ...
newscase
Hims & Hers: The Costly Pivot to Brand-Name Weight Loss Drugs
The stock of telehealth provider Hims & Hers is caught in a classic Wall Street tug-of-war. On one side, CEO Andrew Dudum is touting explosive early demand ...
Barron's
Hims & Hers Health Inc.
About Hims & Hers Health Inc. Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental ...